Cellular immunotherapy: Complexity of immune system and industrial development;L'immunothérapie cellulaire: Complexité du système immunitaire et développement industriel

Bulletin du Cancer

Volumn 90, Issue 8-9, 2003, Pages 789-794

  Abastado, J P ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Cell immunoth rapy; Immune system

Indexed keywords

VACCINE;

ADOPTIVE IMMUNOTHERAPY; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; INDUSTRIAL PRODUCTION; MEDICAL RESEARCH; MESOTHELIOMA; OVARY CARCINOMA; REVIEW; TREATMENT PLANNING;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MESOTHELIOMA; MODELS, ANIMAL; OVARIAN NEOPLASMS; QUALITY CONTROL; T-LYMPHOCYTES; URINARY BLADDER NEOPLASMS;

EID: 0141991266     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Benkirane R. Spirales de l'auto-organisation, entretien avec Stuart Kauffman. In : La complexité, vertiges et promesses. Ed. Le Pommier, 2002 ; p. 207.
2. Changeux JP, Connes A. Matière à pensée. Odile Jacob 1989 ; 127.
3. Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J, Kourilsky P. Diversity of human alpha beta T cell receptors. Science 2000; 288 : 1135.
4. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998 ; 396 : 690-5.
5. Yewdell JW. Not such a dismal science : the economics of protein synthesis, folding, degradation and antigen processing. Trends Cell Biol 2001 ; 11 : 294-7.
6. Mackay CR. Dual personality of memory T cells. Nature 1999 ; 401 : 659-60.
7. Ainslie MP, McNulty CA, Huynh T, Symon FA, Wardlaw AJ. Characterisation of adhesion receptors mediating lymphocyte adhesion to bronchial endorhelium provides evidence for a distinct lung homing pathway. Thorax 2002 ; 57 : 1054-9.
8. Bergé P, Dubois M. Chaos déterministe expérimental et attracteurs étranges. In : Chaos et déterminisme. Ed. A. Dahan Dalmedico, J.-L. Chabet, and K. Chemla, Edition du Seuil, collection Points, 1992 ; p. 115-169.
9. Benkirane R. Emergence et insectes sociaux, entretien avec J.-L. Deneubourg. In : La complexité, vertiges et promesses. Ed. L. Pommier, 2002 ; p. 95-118.
10. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunol 2002 ; 3 : 991-8.
11. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001 ; 411 : 1058-64.
12. Ricciardi-Castagnoli P, Granucci F. Opinion : Interpretation of the complexity of innate immune responses by functional genomics. Nature Rev Immunol 2002 ; 2 : 881-9.
13. Sacks O. L'homme qui prenait sa femme pour un chapeau. Editions du Seuil, collection Points, 1988 ; 125-36.
14. Bachoud-Levi AC, Hantraye P, Peschanski M. Feral neural grafts for Huntingron's disease : a prospective view. Mov Disord 2002 ; 17 : 439-44.
15. Fanger NA, Maliszewski CR, Schooley K, Griffith TS. Human dendritic cells mediate cellular apoprosis via tumor necrosis factor-related apoprosis-inducing ligand (TRAIL). J Exp Med 1999 ; 190 : 1155-64.
16. Joo HG, Fleming TP, Tanaka Y, Dunn TJ, Linehan DC, Goedegebuure PS, et al. Human dendritic cells induce tumor-specific apoprosis by soluble factors. Int J Cancer 2002 ; 102 : 20-8.
17. Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interfeton alpha/beta-producing cells link innare and adaptive immunity. J Exp Med 2000 ; 192 : 219-26.
18. de Jong EC, Vieira PL, Kalinski P, Schuitemaker JH, Tanaka Y, Wierenga EA, et al. Microbial compounds selectively induce Th1 cell-promoting or Th2 cell-promoting dendritic cells in vitro with diverse rh cell-polarizing signals. J Immunol 2002 ; 168 : 1704-9.
19. Granucci F, Vizzardelli C, Pavelka N, Feau S, Persico M, Virzi E, et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nature Immunol 2001 ; 2 : 882-8.
20. Kaech SM, Hemby S, Kersh E, Ahmed R. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002 ; 111 : 837-51.
21. Goxe B, Latour N, Bartholeyns J, Romet-Lemonne JL, Chokri M. Monocyte-derived dendritic cells : development of a cellular processor for clinical applications. Res Immunol 1998 ; 149 : 643-6.
22. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nature Med 2000 ; 6 : 332-6.
23. Bostanci A, Vogel G. Research misconduct. German inquity finds flaws, not fraud. Science 2002 ; 298 : 1531-3.
24. Abenhaim L, Louvard D. Rapport de la commission d'orientation sur le cancer 2003 ; 33-34.
25. Paul S, Calmels B, Acres RB. Improvement of adoptive cellular immunotherapy of human cancer using ex-vivo gene transfer. Curr Gene Ther 2002 ; 2 : 91-100.
26. Dumont S, Hartmann D, Poindron P, Oberling F, Faradji A, Bartholeyns J. Control of the antitumoral activity of human macrophages produced in large amounts in view of adoptive transfer. Eur J Cancer Clin Oncol 1988 ; 24 : 1691-8.
27. Bartholeyns J, Lopez M, Andreesen R. Adoptive immunotherapy of solid tumors with activated macrophages : experimental and clinical results. Anticancer Res 1991 ; 11 : 1201-4.
28. Boyer A, Andreu G, Romer-Lemonne JL, Fridman WH, Teillaud JL. Generation of phagocytic MAK and MAC-DC for therapeutic use : characterization and in vitro functional properties. Exp Hematol 1999 ; 27 : 751-61.
29. Monnet I, Breau JL, Moro D, Lena H, Eymard JC, Menard O, et al. Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma : a phase II study. Chest 2002 ; 121 : 1921-7.
30. Thiounn N, Pages F, Mejean A, Descotes JL, Fridman WH, Romet-Lemonne JL. Adoptive immunotherapy for superficial bladder cancer with autologous macrophage activated killer cells. J Urol 2002 ; 168 : 2373-6.
31. de Gramont A, Gangji D, Louvet C, Garcia ML, Tardy D, Romet-Lemonne JL. Adoptive immunotherapy of ovarian carcinoma. Gynecol Oncol 2002 ; 86 : 102-3.
32. Boccaccio C, Jacod S, Kaiser A, Boyer A, Abastado JP, Nardin A. Identification of a clinical-grade maturation factor for dendtiric cells. J Immunother 2002 ; 25 : 88-96.
33. Kaiser A, Bercovici N, Abasrado JP, Nardin A. Naive CD8 + T cell recruitment and proliferation are dependent on stage of dendritic cell maturation. Eur J Immunol 2003 ; 33 : 162-71.
34. Moingeon P. Cancer vaccines. Vaccine 2001 ; 19 : 1305-26.
35. Nonaka M, Yamada-Namikawa C, Flajnik MF, Du Pasquier L. Transspecies polymorphism of the major histocompatibility complex-encoded proteasome subunit LMP7 in an amphibian genus, Xenopus. Immunogenetics 2000 ; 51 : 186-92.
36. Lankar-Burrgereir B, Tampe R. The transporter associated with antigen processing TAP : structure and function. FEBS Lett 1999 ; 464 : 108-12.
37. Robinson J, Waller MJ, Parham P, Bodmer JG, Marsh SG. IMGT/HLA Database: a sequence database for the human major histocompatibility complex. Nucleic Acids Res 2001 ; 29 : 210-3.
38. Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 2001 ; 22 : 41-7.
39. Simon R. Bayesian design and analysis of active control clinical trials. Biometrics 1999 ; 55 : 484-7.
40. Bercovici N, Duffour MT, Agrawal S, Salcedo M, Abastado JP. New methods for assessing T-cell responses. Clin Diagn Lab Immunol 2000 ; 7 : 859-64.
41. Romero P, Cerottini JC, Waanders GA. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol Med Today 1998 ; 4 : 305-12.
42. Petricoin EF, Ardekani AM, Hirt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002 ; 359 : 572-7.